Psilocybe Ingeli: A Newer, Stronger, Psychedelic Mushroom?

Q: Where was Psilocybe ingeli discovered?

Psilocybe ingeli was first observed and clinically reported in 2024 by researchers van der Merwe & colleagues after it was discovered fruiting in manure-enriched grassland in the mountainous Kwa-Zulu Natal region of South Africa. It was first observed and collected in the field by citizen mycologist Talan Moult, who noticed two mushrooms growing through the grass while clearing a plot for his beehives.

Q: Is P. ingeli safe to consume?

All psychedelic mushrooms carry risk. P. ingeli, based on anecdotal reports (there’s no published clinical evidence on its acute effects yet), seems to be generally safe, if more potent than other species.

If you’re a fan of fungi, it’s an exciting time - new species are emerging at incredible speeds. Take the recently discovered Psilocybe ingeli. P. ingeli came into focus in 2024 and has been a species of growing interest for the mycology community. The arrival of P. ingeli on the scene underscores the vital role of knowledgeable citizen mycologists in under-surveyed regions of the world, such as Africa, in the discovery of such species.

Here’s what we know about P. ingeli thus far, including origins & classification, reported effects, and the safety protocols you should take when interacting with or consuming psychedelic mushrooms.

What to Know About Psilocybe ingeli

In September 2024, mycologists van der Merwe & colleagues published work in the journal Mycologia concerning two emergent species of psychedelic mushrooms discovered in Africa: P. ingeli (and P. maluti, for another time), among the latest in a string of new Psilocybe species.

Quick Facts

Genus: Psilocybe
Potency: High to very high
Notable Traits: A strong indigo blueing reaction when handled, slender 3-7cm stem

P. ingeli grows in clusters and bears a distinct caramel colored cap with a lighter rim. It may even somewhat resemble a pancake. Mature caps of P. ingeli resemble small, wavy caps (Psilocybe cyanescens) mushrooms in both shape and coloration. Van der Merwe & Co. remarked that P. ingeli bears a strong resemblance to other fungi in the Psilocybe genus, with its closest relative being P. keralensis.

Africa seems to be a hotbed of mycological potential. Other researchers have noted that, “There are now six known indigenous species of psychedelic mushrooms in the genus Psilocybe…” alongside the roughly 140 observed worldwide.

Psilocybe ingeli Potency

Initial analyses of dried P. ingeli mushrooms have indicated total alkaloid levels ranging from 2.3% to 4.2% by dry weight. This places it among the most potent magic mushrooms known, in the same potency ballpark as other highly potent species such as Panaeolus cyanescens and P. zapotecorum.

Flat vector illustration of a mycologist in a field hat examining Psilocybe ingeli mushrooms growing in grassland with a magnifying glass and open field guide, depicting citizen mycologist identification of new Psilocybe species in Africa.

To put the potency of P. ingeli into context, most clinical studies involving psilocybin use a (high) dose of 25 mg of the pure compound. This means that at its upper potency levels, just 1 gram of dried mushroom material could potentially harbor this dosage of psilocybin (or more) and could result in a deep and immersive experience, so newcomers to this mushroom should tread carefully when dosing.

This makes it generally a far more potent species than P. cubensis, which typically ranges from 0.5-1% alkaloids. While some batches of P. cubensis may attain over 2% potency levels on occasion, this is the result of decades of strain selection work. Like all psilocybin mushrooms, potency can vary widely, as can individual sensitivities.

Reported Effects & Experiences With Psilocybe ingeli

As a species that is new on the scene, there is a lack of clinical data with regard to P. ingeli’s acute effects. That said, as part of the Psilocybe genus, we can assume ingeli elicits effects similar to P. cubensis and other better-known species.

Flat vector illustration of a researcher in a lab coat weighing a glowing Psilocybe ingeli mushroom on a digital scale while taking notes on a clipboard, with a jar of dried mushrooms on the desk and large pastel-colored psilocybin mushrooms in the background, representing scientific potency measurement and alkaloid research.

Hobbyist mycologists have grown and tested P. ingeli. Anecdotally, one user contextualized ingeli by comparing it against the default 25-milligram dose of lab-grown psilocybin used in clinical research: “It isn’t shabby in the potency stakes.”

Psilocybe Ingeli Effects & Research

Other users have put forth anecdotal reports of their experience with P. ingeli trips. 0.3g seems to have produced “giddiness within 30 minutes … the trip came on slowly, with ingestion occurring at 8:30 PM and intensifying by 10:15.”

“The experience evolved into something very visual,” the tester continued. “Colors became very interesting and warped … What also stood out about this species was that it might be [easier] on the system for people who are sensitive to side effects like headaches or nausea.”

Another user, who reportedly ingested 0.76g of P. ingeli in a tea, characterized it as “One of the best and strongest I’ve eaten.”

Flat vector illustration of a person consulting with a therapist or guide in a cozy office setting, with a diverse array of colorful psilocybin mushroom species including Amanita, Liberty Cap, and Psilocybe cubensis displayed in the background, representing harm reduction counseling and informed decision-making before consuming psychedelic mushrooms.

It seems to be a species held in high regard by those psilonauts that have sampled it, with a few testimonials reporting it to be smoother on the system with less body load issues in comparison to P. cubensis.

It’s worth noting that these reports are unsubstantiated, uncontrolled, and may not hold up in a laboratory setting. Still, early anecdotal reports help us glean deeper insights about emergent fungal species.

Psilocybe ingeli Origins & Classification

Kingdom: Fungi
Phylum: Basidiomycota
Class: Agaricomycetes
Order: Agaricales
Family: Hymenogastraceae

Where Psilocybe ingeli Grows Naturally

P. ingeli was found growing in manure-enriched pastureland in the Kwa-Zulu Natal province of South Africa (in a habitat and location that it shares with the species P. natalensis). It was first observed and collected in the field by citizen mycologist Talan Moult, who noticed two mushrooms growing through the grass while clearing a plot for his beehives. P. ingeli gets its name from the Ingeli mountain range, where it was found propagating, like most Psilocybes, among animal droppings.

Psilocybe ingeli Safety, Legal Status, & Harm Reduction

Psychedelic mushrooms have varying legal status. In the United States, psychedelics are classified and regulated as Schedule-I controlled substances by the U.S. Drug Enforcement Agency, making them federally illegal to possess, ingest, or distribute.

That said, states like Colorado and Oregon have loosened restrictions on psychoactive mushrooms due to their clinical potential in managing some mental illnesses when other treatments fall short.

No matter what, it’s best to check local laws and ordinances before you decide to engage with any psychedelic mushroom. Moreover, there are risks associated with ingestion. Certain clinical studies have shown that psilocybin may intensify psychotic disorders; before taking the plunge, do plenty of research or seek out a clinic or retreat with qualified staff.

Frequently Asked Questions

Where was Psilocybe ingeli discovered?

Psilocybe ingeli was first observed and clinically reported in 2024 by researchers van der Merwe & colleagues after it was discovered fruiting in manure-enriched grassland in the mountainous Kwa-Zulu Natal region of South Africa. It was first observed and collected in the field by citizen mycologist Talan Moult, who noticed two mushrooms growing through the grass while clearing a plot for his beehives.

Is P. ingeli safe to consume?

All psychedelic mushrooms carry risk. P. ingeli, based on anecdotal reports (there’s no published clinical evidence on its acute effects yet), seems to be generally safe, if more potent than other species.

Sources

van der Merwe B, Rockefeller A, Kilian A, Clark C, Sethathi M, Moult T, Jacobs KA (2024) description of two novel Psilocybe species from southern Africa and some notes on African traditional hallucinogenic mushroom use. Mycologia 116(5): 821-834. doi: 10.1080/00275514.2024.2363137. Epub 2024 Jul 2. PMID: 38953774.
Moosa-Battey, R. M. (2025). Psilocybin: Revealing the enigmas of a revolutionary fungi. South African Pharmaceutical Journal 92(1): 11–16.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine 387(18): 1637-1648. doi: 10.1056/NEJMoa2206443. PMID: 36322843.
Simonsson O, Goldberg SB, Osika W, Stenfors CUD, Chaturvedi S, Swords CM, Narayanan J, Hendricks PS. (2025) Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychological Medicine 55: e99. doi: 10.1017/S0033291725000716. PMID: 40162511; PMCID: PMC12094617.